Bio Details

Richard Chin, M.D., has served on our board of directors since June 2025. Since January 2026, he has served as the Chief Executive Officer of EmberWorks, LLC, an off-grid telecommunications company, and has also served as the Chief Executive Officer and a board member of AdoraPet Biosciences, Inc., a biotechnology startup focused on pets, since August 2022. Since September 2021, Dr. Chin has served as the managing director of Ascendant Venture LLC, a family office and venture studio that has incubated several life sciences companies. From 2012 to 2021, he served as Chief Executive Officer and a board member of Kindred Biosciences, Inc., a public biotechnology company focused on companion animals that was acquired by Elanco in 2021. From 2008 to 2011, Dr. Chin served as Chief Executive Officer of Institute for OneWorld Health, a non-profit biotechnology company developing drugs for neglected diseases. In addition, from 2006 to 2008, he served as Chief Executive Officer of OXiGENE, Inc., a public biotechnology company developing vascular targeting drugs for oncology and ophthalmology. Prior to that, Dr. Chin served in various leadership roles in clinical development and medical affairs. He currently serves on the board of directors of several private bioscience companies, including Bio Usawa Inc., VETmAb Biosciences, Inc. and Lifeguard Biosciences, Inc., as well as two non-profit organizations, the Center for Asian American Media and the Sand Mandala Foundation.

Dr. Chin holds a B.A. in biology from Harvard College, an M.A. and B.A. in law from Oxford University, and a medical degree from Harvard Medical School.